Dasatinib Combined With Docetaxel For Castration-Resistant Prostate Cancer: Results From a Phase 1/2 Study

BACKGROUND: To determine the potential efficacy of targeting both the tumor and bone microenvironment in patients with castration-resistant prostate cancer (CRPC), we conducted a phase 1/2 trial combining docetaxel with dasatinib, an oral SRC inhibitor. METHODS: In phase 1, 16 men received dasatinib...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Araujo, John C, Mathew, Paul, Armstrong, Andrew J, Braud, Edward L, Posadas, Edwin, Lonberg, Mathew, Gallick, Gary E, Trudel, Géralyn C, Paliwal, Prashni, Agrawal, Shruti, Logothetis, Christopher J
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3898168/
https://ncbi.nlm.nih.gov/pubmed/21976132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26204
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars